PriceTargets.com logo

Tilray - TLRY Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $2.63
  • Forecasted Upside: 103.49%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.29 As of 11/20/2024 01:00 AM ET
▼ -0.02 (-1.53%)

This chart shows the closing price for TLRY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tilray Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TLRY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TLRY

Analyst Price Target is $2.63
▲ +103.49% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Tilray in the last 3 months. The average price target is $2.63, with a high forecast of $4.00 and a low forecast of $1.75. The average price target represents a 103.49% upside from the last price of $1.29.

This chart shows the closing price for TLRY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 investment analysts is to hold stock in Tilray. This rating has held steady since July 2023, when it changed from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 2 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/11/2024Roth MkmLower TargetNeutral ➝ Neutral$2.00 ➝ $1.75
4/10/2024Canaccord Genuity GroupLower TargetBuy$4.25 ➝ $4.00
4/10/2024CIBCLower TargetNeutral ➝ Neutral$2.25 ➝ $2.00
4/5/2024Alliance Global PartnersBoost TargetNeutral$2.25 ➝ $2.75
10/5/2023Alliance Global PartnersBoost Target$2.00 ➝ $2.25
9/1/2023Roth MkmReiterated RatingNeutral ➝ Neutral$2.50
7/27/2023CIBCLower Target$2.75 ➝ $2.25
7/27/2023ATB CapitalBoost Target$2.50 ➝ $3.00
7/27/2023Piper SandlerLower Target$3.00 ➝ $2.00
7/27/2023Alliance Global PartnersLower Target$3.00 ➝ $2.00
4/12/2023Roth CapitalReiterated RatingNeutral
4/11/2023TD CowenLower TargetOutperform$9.00 ➝ $5.00
2/9/2023Atb Cap MarketsReiterated RatingSector Perform
1/9/2023Alliance Global PartnersLower TargetNeutral$4.00 ➝ $3.00
11/1/2022Sanford C. BernsteinInitiated CoverageMarket Perform$3.90
10/13/2022Haywood SecuritiesLower Target$3.50
10/10/2022Cantor FitzgeraldBoost TargetNeutral$4.15 ➝ $4.50
9/30/2022BarclaysLower TargetUnderweight$4.50 ➝ $2.00
8/2/2022Cantor FitzgeraldLower TargetNeutral$5.75 ➝ $4.15
7/29/2022CowenLower Target$23.00 ➝ $9.00
7/29/2022CowenLower Target$23.00 ➝ $9.00
7/29/2022BenchmarkDowngradeHold ➝ Sell$3.00
7/15/2022Roth CapitalLower TargetNeutral$8.00 ➝ $4.00
6/24/2022Cantor FitzgeraldReiterated RatingNeutral$6.15 ➝ $5.75
6/15/2022Canaccord Genuity GroupLower Target$9.00 ➝ $7.00
6/15/2022Piper SandlerLower TargetNeutral$6.00 ➝ $3.00
5/2/2022Alliance Global PartnersLower TargetNeutral$8.00 ➝ $5.50
4/20/2022BarclaysLower TargetUnderweight$8.50 ➝ $4.50
4/7/2022Cantor FitzgeraldBoost TargetNeutral$6.90 ➝ $8.40
3/17/2022Piper SandlerLower TargetNeutral$8.00 ➝ $6.00
3/4/2022Canaccord Genuity GroupUpgradeHold ➝ Buy$9.00
1/11/2022MKM PartnersLower TargetNeutral ➝ Neutral$10.00 ➝ $8.00
1/7/2022Alliance Global PartnersLower Target$12.00 ➝ $7.00
1/7/2022Cantor FitzgeraldLower TargetNeutral$11.80 ➝ $7.40
11/18/2021BarclaysInitiated CoverageUnderweight$10.00
11/1/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral$18.00 ➝ $11.80
10/20/2021Jefferies Financial GroupReiterated RatingBuy
10/8/2021CIBCLower TargetNeutral$14.00 ➝ $12.00
10/8/2021Stifel NicolausLower TargetHold$11.50 ➝ $10.00
9/17/2021Cantor FitzgeraldLower TargetOverweight$19.00 ➝ $18.00
9/16/2021Roth CapitalLower TargetNeutral$25.00 ➝ $12.00
9/10/2021Piper SandlerLower TargetNeutral$15.00 ➝ $14.00
8/18/2021Alliance Global PartnersLower TargetNeutral$17.00 ➝ $15.00
7/29/2021MKM PartnersReiterated RatingHold$16.00
7/27/2021Cantor FitzgeraldLower TargetOverweight$24.00 ➝ $19.00
6/30/2021MKM PartnersReiterated RatingNeutral ➝ Hold$8.50 ➝ $16.00
6/23/2021Alliance Global PartnersLower TargetNeutral$32.00 ➝ $18.00
6/10/2021CIBCDowngradeOutperform ➝ Neutral$25.00
6/2/2021Cantor FitzgeraldUpgradeNeutral ➝ Overweight$30.25 ➝ $22.00
5/11/2021CowenInitiated CoverageOutperform
5/7/2021Jefferies Financial GroupUpgradeUnderperform ➝ Buy$4.77 ➝ $23.00
4/28/2021Bank of AmericaInitiated CoverageBuy
2/25/2021Piper SandlerReiterated RatingOverweight ➝ Neutral$15.00 ➝ $26.00
2/25/2021BenchmarkReiterated RatingBuy ➝ Hold
2/18/2021Roth CapitalBoost Target$10.00 ➝ $25.00
2/18/2021Alliance Global PartnersBoost TargetBuy ➝ Neutral$18.00 ➝ $32.00
2/18/2021BMO Capital MarketsBoost TargetPositive ➝ Market Perform$9.00 ➝ $22.00
2/18/2021Piper SandlerDowngradeOverweight ➝ Neutral$15.00 ➝ $26.00
2/18/2021BenchmarkDowngradeBuy ➝ Hold
2/16/2021Cantor FitzgeraldBoost TargetNeutral$24.20 ➝ $30.25
1/15/2021Cantor FitzgeraldBoost TargetNeutral$11.00 ➝ $24.20
12/17/2020Stifel NicolausUpgradeSell ➝ Hold
11/16/2020Jefferies Financial GroupDowngradeHold ➝ Underperform$5.60 ➝ $4.77
11/11/2020Stifel NicolausDowngradeHold ➝ Sell$6.00 ➝ $4.75
11/9/2020Cantor FitzgeraldLower TargetNeutral$12.00 ➝ $11.00
10/1/2020MKM PartnersLower TargetNeutral$8.00 ➝ $6.00
9/21/2020Jefferies Financial GroupUpgradeUnderperform ➝ Hold$5.60
8/11/2020Alliance Global PartnersReiterated RatingNeutral
8/11/2020Cantor FitzgeraldLower TargetNeutral$8.00 ➝ $7.90
8/11/2020Northland SecuritiesReiterated RatingHold
8/10/2020OppenheimerReiterated RatingHold
6/16/2020OppenheimerReiterated RatingHold
5/19/2020MKM PartnersBoost TargetHold$5.00 ➝ $8.00
5/12/2020Northland SecuritiesReiterated RatingHold
5/12/2020Stifel NicolausBoost TargetHold$5.50 ➝ $6.50
5/12/2020BenchmarkLower TargetBuy$28.00 ➝ $14.00
5/12/2020Alliance Global PartnersLower TargetNeutral$15.00 ➝ $9.00
5/11/2020Cantor FitzgeraldBoost TargetNeutral$4.90 ➝ $7.00
4/16/2020Jefferies Financial GroupDowngradeHold ➝ Underperform$5.00
4/9/2020Consumer EdgeDowngradeOverweight ➝ Equal Weight
3/23/2020Roth CapitalLower Target$15.00 ➝ $4.00
3/19/2020Bank of AmericaDowngradeSell
3/3/2020Cantor FitzgeraldReiterated RatingHold$10.00
3/3/2020Jefferies Financial GroupReiterated RatingHold$17.00
3/3/2020Stifel NicolausLower TargetIn-Line ➝ Hold$18.00 ➝ $14.50
3/3/2020BenchmarkLower TargetPositive ➝ Buy$28.00 ➝ $12.00
3/3/2020Eight CapitalDowngradeBuy ➝ Neutral$16.00
3/2/2020Cantor FitzgeraldLower TargetNeutral$26.00 ➝ $19.50
2/27/2020Bank of AmericaLower TargetNeutral$22.00 ➝ $20.00
2/24/2020CowenDowngradeOutperform ➝ Market Perform$40.00 ➝ $20.00
1/13/2020Bank of AmericaInitiated CoverageNeutral$18.00
12/12/2019Roth CapitalReiterated RatingHold
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 27 very positive mentions
  • 34 positive mentions
  • 19 negative mentions
  • 2 very negative mentions
Mentions as of
4/25/2024
  • 21 very positive mentions
  • 39 positive mentions
  • 8 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 9 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 12 very positive mentions
  • 27 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 13 very positive mentions
  • 53 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 6 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 9 very positive mentions
  • 41 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2024
  • 12 very positive mentions
  • 36 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 12 very positive mentions
  • 36 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Tilray logo
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.
Read More

Today's Range

Now: $1.29
Low: $1.28
High: $1.33

50 Day Range

MA: $1.63
Low: $1.31
High: $1.81

52 Week Range

Now: $1.29
Low: $1.28
High: $2.97

Volume

27,680,158 shs

Average Volume

25,532,475 shs

Market Capitalization

$1.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Tilray?

The following sell-side analysts have issued reports on Tilray in the last year: Alliance Global Partners, Canaccord Genuity Group Inc., CIBC, and Roth Mkm.
View the latest analyst ratings for TLRY.

What is the current price target for Tilray?

0 Wall Street analysts have set twelve-month price targets for Tilray in the last year. Their average twelve-month price target is $2.63, suggesting a possible upside of 103.5%. Canaccord Genuity Group Inc. has the highest price target set, predicting TLRY will reach $4.00 in the next twelve months. Roth Mkm has the lowest price target set, forecasting a price of $1.75 for Tilray in the next year.
View the latest price targets for TLRY.

What is the current consensus analyst rating for Tilray?

Tilray currently has 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TLRY, but not buy more shares or sell existing shares.
View the latest ratings for TLRY.

What other companies compete with Tilray?

Other companies that are similar to Tilray include Cronos Group, USANA Health Sciences, ChromaDex, Mind Medicine (MindMed) and Canopy Growth. Learn More about companies similar to Tilray.

How do I contact Tilray's investor relations team?

Tilray's physical mailing address is 265 Talbot Street West Leamington, ON N8H 5L4 Canada. The company's listed phone number is 206-432-9325 and its investor relations email address is [email protected]. The official website for Tilray is www.tilray.com. Learn More about contacing Tilray investor relations.